Scholarlink

<p>Targeted protein degradation (TPD) is an innovative therapeutic approach that bypasses traditional drug inhibition methods. Proteolysis-targeting chimeras (PROTACs) are bifunctional molecules that harness degradation machinery to remove target proteins. This review examines the evolution of PROTACs and their application in targeting microorganisms that develop drug resistance, covering their development, advancements in linker design, E3 ligase selection, and delivery methods, including nanoparticles and exosomes.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evolution of proteolysis-targeting chimeras (PROTAC) technology to overcome challenges of antimicrobial resistance

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月4日

查看全文
  • Dhanashree N. Sarwan,
  • Pramod B. Khedekar,
  • Ritesh P. Bhole,
  • Rupesh V. Chikhale

摘要

Targeted protein degradation (TPD) is an innovative therapeutic approach that bypasses traditional drug inhibition methods. Proteolysis-targeting chimeras (PROTACs) are bifunctional molecules that harness degradation machinery to remove target proteins. This review examines the evolution of PROTACs and their application in targeting microorganisms that develop drug resistance, covering their development, advancements in linker design, E3 ligase selection, and delivery methods, including nanoparticles and exosomes.